Glycoprotein IIb/IIIa inhibitors
Several GpIIb/IIIa inhibitors exist:
They may also be used to treat acute coronary syndromes, without percutaneous coronary intervention, depending on TIMI risk.
They should be given intravenously. The oral form is associated with increased mortality and hence should not be given.
In integrin nomenclature glycoprotein IIb/IIIa is called αIIbβ3.